PMID: 7007854Jan 1, 1981Paper

Acute myeloblastic leukemia following non-Hodgkin lymphoma in an adolescent. A report of a case with preleukemic syndrome, and review of the literature

Medical and Pediatric Oncology
P KaurP A Meyers

Abstract

Reports of acute nonlymphoblastic leukemia occurring after successful treatment of Hodgkin and non-Hodgkin lymphoma (NHL) are appearing with increasing frequency. Two years after completion of LSA2-L2 therapy for stage III, poorly differentiated lymphocytic lymphoma, a 16-year-old boy developed a preleukemic state characterized by a refractory macrocytic anemia with excess blasts, dyshematopoiesis, abnormal cluster:colony ratio on in vitro bone marrow culture, and acquired deficiencies of erythrocyte pyruvate kinase, triose phosphate isomerase, and adenylate kinase. Four months later acute myeloblastic leukemia was evident. The RNA index determined by flow cytofluorometry was increased. Four marker chromosomes were found and involved complex translocation of chromosomes 11 and 17 (t11;l17) in 100% of the cells, and chromosomes 4 (t4q;4) in 10% of the cells. A thorough literature search uncovered four other reports of acute nonlymphoblastic leukemia occurring in children treated for NHL and a total of 58 cases in the adult and pediatric age groups. Over 50% of the patients had AML, were mean over 50 years of age, and were treated with radiotherapy and chemotherapy. It is anticipated that additional cases of second malignancies w...Continue Reading

References

Jan 1, 1978·Acta Haematologica·F CavalliH G Ryssel
Jan 1, 1979·Medicine·D A Casciato, J L Scott
Jul 1, 1979·Cancer·H MorseA Robinson
Nov 1, 1979·Pediatric Research·A HagemeijerK Hählen
Jan 1, 1979·Medical and Pediatric Oncology·R E HarrisR L Baehner
Aug 1, 1978·Cancer·J W Linman, G C Bagby
Mar 1, 1979·The New England Journal of Medicine·J G KrikorianH S Kaplan
Jan 15, 1976·International Journal of Cancer. Journal International Du Cancer·L ZechG Klein
Jan 1, 1976·American Journal of Hematology·W W ZuelzerM J Ottenbreit
Dec 1, 1975·British Journal of Haematology·P BoivinA Kahn
Mar 1, 1975·The American Journal of Medicine·F Rosner, H Grünwald
Jan 1, 1975·Medical and Pediatric Oncology·N WollnerM L Murphy
Oct 1, 1974·Archives of Internal Medicine·R T SteigbigelS L Schrier
Nov 1, 1972·Cancer·R B WeissB J Kennedy
Mar 1, 1971·Cancer·S LowenbraunA A Serpick
Nov 30, 1972·The New England Journal of Medicine·J C ArseneauV T DeVita
Nov 1, 1971·Archives of Internal Medicine·J L PothS L Schrier
Apr 1, 1967·Cancer·J Laszlo, H E Grode
Feb 1, 1961·Medicine·S A ROSENBERGL F CRAVER
Jul 1, 1960·Annals of Internal Medicine·J H HORNBAKER

❮ Previous
Next ❯

Citations

Jul 1, 1982·Indian Journal of Pediatrics·R S Chaganti
Jan 1, 1986·Critical Reviews in Oncology/hematology·M L Bernstein, M J Vekemans
Jan 1, 1984·Medical and Pediatric Oncology·M P LinkB E Glader
Jan 1, 1986·Scandinavian Journal of Haematology. Supplementum·R Wegelius

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.